Table 2.
Demographic and clinical characteristics of cisplatin-treated pediatric medulloblastoma patients at Texas Children’s Hospital (n = 71), 1987–2010
| Cases1 (n = 26) | Controls (n = 45) | P-value | |
|---|---|---|---|
| Mean age at diagnosis, year (range) | 6.2 (0.7–15.8) | 7.5 (1.1–18.0) | 0.19 |
| Mean cisplatin, cumulative mg/m2 (range) | 307 (100–525) | 339 (105–720) | 0.17 |
| Tumor diagnosis, n (%) | 0.14 | ||
| Supratentorial PNET | 3 (12) | 1 (2) | |
| Medulloblastoma | 23 (88) | 44 (98) | |
| Surgical procedure, n (%)2 | 0.06 | ||
| Biopsy only | 1 (4) | 0 (0) | |
| Total resection | 15 (60) | 37 (82) | |
| Less than total resection | 9 (36) | 8 (18) | |
| Male gender, n (%) | 22 (85) | 30 (67) | 0.16 |
| Self-report ethnicity, n (%) | 0.78 | ||
| Non-Hispanic white | 12 (46) | 18 (40) | |
| Hispanic | 9 (35) | 15 (33) | |
| Other | 5 (19) | 12 (27) | |
| Treatment protocol, n (%) | 0.15 | ||
| SJMB-96/SJMB-03/CCG-9961 | 17 (65) | 35 (78) | |
| Other with cisplatin | 9 (35) | 10 (22) | |
| Craniospinal irradiation ≥34 Gy, n (%) | 12 (46) | 10 (22) | 0.06 |
| Amifostine therapy, n (%) | 8 (31) | 20 (44) | 0.32 |
P-value from Student’s t-test or Fisher’s exact test. PNET, primitive neuroectodermal tumors.
1
Defined as use of a hearing aid device following the initiation of primary therapy.
2
Incomplete information on n = 2 participants.